Skip to main content
MANE logo

MANE · Veradermics, Inc

Track MANE — free
$119.52 -4.87 (-3.92%) At close · Nov 20
Market Cap
$5.04B
Shares
42.20M
Volume · Nov 20 375.02K Avg daily vol (3M) 733.5K

Price & Indicators

 

Key stats

Close
$119.52
Fri 20 Nov
Open
$121.98
Fri 20 Nov
Average volume, 30 days
676K
shares a session
Short interest
3.4M
8.0% of shares · 5.1 days to cover
Day range
$118.99$124.00
Open $121.98 Close $119.52
Available closing range
$37.03$156.56
Close $119.52 23.7% under the high
Short volume, last session
76%
Last earnings
Oct 19, 2026
Latest filing
10-Q · Nov 10
Price history
Feb 2026 to Nov 2026

The closing range uses available history since Feb 4, 2026; less than a full year is stored.

Up next

Jan 15, 2027 Est · unconfirmed · in 8 wks

Latest documents

2026
Nov 19
Investor event
Oral minoxidil tablet lifts hair counts in male Phase III

Veradermics reports Phase III male pattern hair loss data for its oral minoxidil extended-release tablet, with target area hair count rising from month two. Target area hair count reached 43.9 at month 12, and no treatment-related serious adverse events were seen. The company expects to topline its Phase III female pattern hair loss trial in the first half of 2027.

4 source passages
we also have shown a very clear time course of improvement that starts with month two, where we see a fast onset of hair growth showing our largest reported hair count in the Phase III program to date at month 12 of 43.9 we saw no treatment-related SAEs we look forward to toplining the first ever phase three trial for an oral treatment for female pattern hair loss in the first half of 2027 Open the document at this passage
Nov 10
Quarterly report 10-Q FY2026 Q3, ended Sep 30
VDPHL01 Phase 3 data support hair growth, with funding into 2030

Veradermics reported positive Study ‘304’ Phase 3 results for VDPHL01 in male pattern hair loss. Nine-month net loss was $71.7 million, while $798.4 million of cash, cash equivalents and marketable securities was expected to fund operations into 2030.

Net loss $21M Diluted EPS -$0.50
Read from the MD&A section
4 source passages
In October 2026, we announced positive topline data from our Phase 3 clinical trial, Study ‘304’ evaluating VDPHL01 in males with mild-to-moderate PHL. We have incurred recurring net losses since inception, including net losses of $71.7 million and $48.1 million for the nine months ended September 30, 2026 and 2025, respectively. As of September 30, 2026, we had $798.4 million of cash, cash equivalents and marketable securities. We believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements into 2030, based on our current operating plans. Open the document at this passage
Nov 10
Current report 8-K
Net loss $21.0 million; positive 12-month Study 302 data

Veradermics reported a third-quarter net loss of $21.0 million, versus $20.1 million a year earlier, with $798.4 million in cash and marketable securities. It also announced positive 12-month topline data from Study '302' for VDPHL01 in men.

Financial results
3 source passages
Net loss was $21.0 million for the third quarter of 2026, as compared to a net loss of $20.1 million for the third quarter of 2025. Cash, cash equivalents, and marketable securities totaled $798.4 million as of September 30, 2026. In November 2026, Veradermics announced positive topline results from its Phase 2/3 trial, Study ‘302’, evaluating 12-month long-term safety and efficacy of VDPHL01 in males with mild-to-moderate pattern hair loss. Open the document at this passage
Nov 9
Current report 8-K
VDPHL01 shows sustained hair growth and favorable safety in Study ‘302’

Veradermics reported positive 12-month Study ‘302’ results for VDPHL01: non-vellus hair count increased 43.9 hairs/cm2 with twice-daily dosing and 29.7 hairs/cm2 with once-daily dosing; no new safety signals or treatment-related SAEs were observed.

Regulation FD disclosure, Other events Read from the first part of this long document
3 source passages
Veradermics Achieved the Highest VDPHL01 Reported Hair Count in the Phase 3 Program to Date in Positive 12-Month Study ‘302’ Data in Male Pattern Hair Loss In Part B of Study ‘302’, participants in the VDPHL01 continued group had an increase in non-vellus hair count of 43.9 hairs/cm2 and 29.7 hairs/cm2 in twice-daily (BID) and once-daily (QD) treatment arms from baseline to Month 12, respectively. Treatment with VDPHL01 in the continued group was generally well tolerated through Month 12 with an overall safety profile consistent with Part A of Study ‘302’ and Study ‘304’. No treatment-related SAEs, no AESIs of cardiac origin, and no new safety signals were observed in the study. Open the document at this passage
Oct 19
Current report 8-K
VDPHL01 meets all endpoints in 536-patient male hair loss trial

Veradermics reported positive topline results from Study ‘304’, a placebo-controlled trial of VDPHL01 in men with mild-to-moderate pattern hair loss, meeting all primary and secondary endpoints. Non-vellus hair count rose 28.6 hairs/cm² on once-daily dosing and 36.4 hairs/cm² on twice-daily dosing, versus 6.6 hairs/cm² for placebo at Month 6. No treatment-related serious adverse events were observed.

Regulation FD disclosure, Other events Read from the first part of this long document
5 source passages
Study ‘304’ enrolled 536 participants who were randomized to receive either VDPHL01 8.5mg once daily (QD), VDPHL01 8.5mg twice daily (BID), or placebo. The trial met all primary and secondary endpoints with high statistical significance Participants achieved an average increase in non-vellus hair count of 28.6 hairs/cm² (p<0.0001) and 36.4 hairs/cm² (p<0.0001) in once-daily and twice-daily VDPHL01 treatment arms, respectively. Those receiving placebo showed a 6.6 hairs/cm² increase from baseline at Month 6. No treatment-related SAEs and no AESIs of cardiac origin were observed in the study. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$93.58M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-1.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$132.16M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+5,526.7%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
8.0%
Latest settlement · 5.1 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Jul 15, 2026
Q2 FY26

TL;DR. Veradermics reported positive Phase 2 Study 207 results for VDPHL01 in female pattern hair loss, showing robust hair count gains and high patient-reported improvement with no cardiac safety signals, and completed enrollment in the registration-directed Phase 2/3 Study 306 with topline readout now guided to 1H27; quarterly net loss widened to $23.5M with higher opex while cash position strengthened to $819.9M, funding operations into 2030.

Bullish
  • + Positive Phase 2 Study 207 results showed robust hair count gains in female pattern hair loss with VDPHL01.
  • + High patient-reported improvement in hair coverage supports strong efficacy profile.
  • + No cardiac safety signals or treatment-related SAEs observed in female Phase 2 study.
  • + Completed enrollment in 556-participant registration-directed Phase 2/3 Study 306 in females.
  • + Cash position of $819.9M is expected to fund operations into 2030 through Phase 3 readouts and potential commercial launch.
Bearish
  • − Net loss widened to $23.5M in Q2 2026 from $15.6M in Q2 2025 on higher operating expenses.
  • − R&D and G&A expenses increased significantly year-over-year as headcount and commercial readiness ramped.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +23%
above
Price vs 50-day avg −4%
below
RSI (14) 42
neutral
MACD trend Negative
52-week position 69%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −14%
trailing
6-month return +22%
trailing
Relative strength +31%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $125 › 200d $97 — 50d above 200d
Institutional flow Accumulating
+27% holders QoQ · +63 funds added
Insider flow Distributing
Net -$75.2M over 90 days · 100% sells
Short interest Falling
8.03% of shares out · ▼ -8.4% MoM · 5.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
210 holders — 13F breadth
Squeeze score 69
elevated · 0–100
Fundamentals
Weak
EPS growth −202%
Y/Y
Free cash flow $-71.6M
Balance sheet $21.8M
net cash
Quant / Vol
risk profile
Very High
Volatility 92%
annualized · 1-yr
Max drawdown −25%
past year
ATR 7.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 5 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+23% Bullish
Price vs 50-day avg
−4% Neutral
RSI (14)
42 Neutral
MACD trend
Negative Bearish
52-week position
69% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $125 › 200d $97 — 50d above 200d
Institutional flow Accumulating
+27% holders QoQ · +63 funds added
Insider flow Distributing
Net -$75.2M over 90 days · 100% sells
Short interest Falling
8.03% of shares out · ▼ -8.4% MoM · 5.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
210 holders — 13F breadth
Price context
position in its available closing range
Range low $37 Now $120 · 69% Range high $157
vs 200-day avg +23% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Mean increase in non-vellus target area hair count (TAHC), BID dose arm, Study 302 continued gro 43.9 Month 12 —
Mean increase in non-vellus target area hair count (TAHC), BID dose arm, Study 304 36.4 Month 6 —
Mean increase in non-vellus target area hair count (TAHC), QD dose arm, Study 302 continued grou 29.7 Month 12 —
Mean increase in non-vellus target area hair count (TAHC), QD dose arm, Study 304 28.6 Month 6 —
Total potentially dilutive shares 5,530,902 the three months ended September 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MANE
Veradermics, Inc
this stock
$5.04B — — — 8.0%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
210
% held
86.3%
Net QoQ
+2.5M sh
Top holder
SUVRETTA CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
171
View
Short & Settlement
Short Interest Falling
Shares short
3.4M
Days to cover
5.1d
Change
-309.1K sh
View
Short Volume
Short vol %
76%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
10
Value
$1.2K
As of
Oct 20, 2026
View
Off-Exchange
Off-exchange %
53.2%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$75.2M
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-70.0M
EPS diluted
$-111.91
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 19, 2026
This year
24

Veradermics reports Phase III male pattern hair loss data for its oral minoxidil extended-release tablet, with target area hair count rising from month two. Target area hair count reached 43.9 at month 12, and no treatment-related serious adverse events were seen. The company expects to topline its Phase III female pattern hair loss trial in the first half of 2027.

View
Proposed Sales
Value
$37.6M
Shares
250.0K
Filed
Nov 12, 2026
View
Exempt Offerings
Offering
$30.0M
Filed
May 15, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 19, 2026
View
Investor Relations
Latest news
Veradermics Reports Third Quarter…
Published
Nov 10, 2026
View

Performance

5D 20D 120D MTD YTD
MANE -7.8% -13.9% +21.7% -14.4% —
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +0.7% -4.7% +30.9% -5.7% —
Key facts CIK 1827635 CUSIP 922967104 13F (30d) 200 filings 197 filers Visit website Investor relations